PIK3CA and ovarian clear cell cancer: In the efficacy-evaluable patients who received 24mg 4 days on/3 days off intermittent dosing, objective responses were observed in one patient with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutated endometrial cancer and five patients with ovarian clear cell carcinoma.